

Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features

JJ James^{*1}, AJ Evans¹, SE Pinder¹, E Gutteridge¹, KL Cheung¹, S Chan¹ and JFR Robertson¹

¹Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK

The aim of this study was to identify factors that may be associated with the development of bone metastases in patients with metastatic breast carcinoma and to see if any of these factors had a bearing on subsequent survival. In total, 492 patients presented to the Nottingham City Hospital with metastatic breast carcinoma between July 1997 and December 2001. Of these, 267 patients had bone metastases at presentation with metastatic disease, 91 patients in this group had bone as their only site of metastatic disease. Sites of first presentation of metastatic disease were prospectively recorded, as were histological features of the primary tumour (tumour type, histological grade, lymph node stage, tumour size and oestrogen receptor (ER) status). The radiological features of the bone metastases, the metastasis-free interval and serological tumour marker levels at presentation with metastases were all recorded. There was a significant association between the development of bone metastases and lower grade tumours ($P = 0.019$), ER-positive tumours ($P < 0.0001$) and the lymph node stage of the primary tumour ($P = 0.047$). A multivariate analysis found that metastasis-free interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently contributed to survival from time of presentation with bone metastases.

British Journal of Cancer (2003) **89**, 660–665. doi:10.1038/sj.bjc.6601198 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: breast carcinoma; bone metastases; prognosis; survival

The survival of patients with metastases is variable ranging from a matter of months to many years. The ability to predict prognosis and response to treatment has a considerable impact on patient management. It is well established that oestrogen receptor (ER) status and site of presentation of metastatic disease have the greatest impact on patient survival, with additional contributions made by patient age, disease-free interval and histological grade.

Bone is the most common site of metastases in patients with breast carcinoma and so patients with bone metastases make up the largest single group of patients presenting with metastatic disease. It has previously been reported that 20% of patients with bone metastases survive for more than 5 years, which emphasises the wide variation in survival seen in this group of patients (Coleman *et al*, 1987). The aim of this study was to identify factors that may be associated with the development of bone metastases and to see if any of these factors had any bearing on subsequent survival.

We have assessed traditional factors such as ER status, histological grade, lymph node stage and size of the primary tumour, patient age, metastasis-free interval and the presence of metastases at sites other than bone. We have examined the radiological appearance of the bone metastases and looked for associations with the histological features of the tumour and patient survival. In common with other centres, we increasingly use serological tumour markers in the diagnosis and monitoring of

patients with metastatic breast carcinoma. The prognostic significance of elevated tumour markers at presentation with bone metastases was also studied. Prognostic features were assessed in a univariate and multivariate fashion.

METHOD

Between July 1997 and December 2001, 492 patients presented to our unit with newly diagnosed metastatic breast carcinoma. The group consisted of patients presenting with metastatic disease following a previous diagnosis of breast carcinoma and patients with metastatic disease at the time of initial diagnosis of breast cancer (stage 4).

Virtually all patients were initially investigated for metastatic disease due to a clinical symptom or sign. At presentation, patients were routinely assessed for metastatic disease in the bones, chest and liver. In the first instance, plain radiographs were used to assess the chest and bones. A radiograph of the pelvis was obtained routinely, supplemented with radiographs of any symptomatic areas. Bone metastases visible on the plain radiograph were recorded as being sclerotic, lytic or mixed. Bone scintigraphy, computed tomography (CT) and magnetic resonance (MR) imaging were used when the diagnosis was uncertain or equivocal. Bone lesions not visible on plain radiographs, but identified on the other imaging modalities were described as occult. The presence of liver metastases was determined using ultrasound or less frequently CT. Sites of metastatic disease at first presentation were prospectively recorded.

Tumour markers were recorded at the time of first presentation. The markers routinely measured at our institution are erythrocyte sedimentation rate (ESR), carcinoembryonic antigen (CEA) and

*Correspondence: Dr JJ James, Breast Education Centre, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK;

E-mail: jonathan.james@nibec.co.uk

Received 10 December 2002; revised 1 May 2003; accepted 24 June 2003

cancer antigen 15.3 (CA15.3). CEA was said to be elevated above a value of 10 ng ml^{-1} and CA15.3 was elevated above a level of 35 U ml^{-1} .

Pathological data were obtained from the patients previous mastectomy or wide local excision specimens. Histological grade, lymph node stage, tumour size, ER status and tumour type were recorded for each patient where possible. Tumour types included Ductal No Specific Type (Ductal NST), Tubular Mixed, Lobular, Mixed ductal and lobular and pure tubular; details of the classification of tumour types are well described elsewhere (Ellis *et al*, 1992). The tumour grade was assessed by the Nottingham method (Elston *et al*, 1991). Lymph node stage was determined from the results of axillary node sampling or dissection: stage 1 disease – no nodal involvement; stage 2 disease – three nodes or less containing tumour; stage 3 disease – four or more nodes containing tumour. For patients diagnosed with primary breast cancer before 1995, ER activity was measured using the standard radioligand binding assay on tissue cytosol samples; the threshold for the designation of ER positivity being 10 fmol mg^{-1} of protein. More recently ER status has been determined using immunocytochemical methods, with an H-score > 50 identifying ER-positive tumours. For patients presenting with locally advanced primary tumours, ER status was determined by core biopsy at the time of presentation. In this situation, provisional tumour grade obtained from core biopsy was not included. All the pathology was reported by one of three specialist breast pathologists, using standard pathological techniques.

Metastasis-free interval was calculated. This was defined as the interval between first diagnosis of breast cancer and time of first presentation with metastatic disease. Survival from diagnosis of metastases was determined from the hospital computer system of patient attendances and deaths, contacting the patient's general practitioner and from the local health authorities patient records.

Throughout the study period patient management remained consistent. Endocrine therapy was the preferred first-line method of treatment in patients with metastatic breast carcinoma. Exceptions to this were patients with widespread or life-threatening visceral metastases. These patients and those with ER-negative tumours were advised to have chemotherapy, if considered fit. The endocrine treatments of choice included the ER antagonist Tamoxifen or an aromatase inhibitor (Anastrozole). Gonadorelin analogues (Goserelin) were used in premenopausal women to achieve ovarian ablation. Bisphosphonates were prescribed routinely for patients with bone metastases according to a defined protocol.

Survival curves were calculated for each factor analysed, using the Kaplan–Meier method. A Cox multivariate analysis was used to establish which of the factors independently contributed towards prolonged survival after the presentation with bone metastases. The statistical analysis was performed using StatView 5.0 for Apple Macintosh (SAS Institute Inc., Cary, NC, USA).

RESULTS

The distribution of metastatic disease in the patient group is shown in Table 1. Bone metastases were the most frequently observed metastases. In all, 267 (54%) patients had bone metastases as their first site of presentation of metastatic disease. Of these, 170 patients had no evidence of bone metastases at presentation. Baseline bone investigations were not performed or incomplete in 55 patients presenting with metastases at other sites. These patients were excluded from subsequent analysis. In all, 91 patients had bone metastases as their only site of metastatic disease at presentation.

The patient and tumour characteristics of the study population ($n = 437$) are shown in Table 2. There is a significant relationship between bone metastases as the first presentation of metastatic

Table 1 Sites of first presentation of metastatic breast carcinoma

Site of first presentation of metastases	Number of patients (%) (n = 492)
Bone	267 (54)
Bone metastases only	91
Bone metastases and other metastases	176
Nonbony metastases only	170
Chest	186 (38)
Liver	144 (29)
Ascites	19 (4)
Brain	15 (3)
Ovarian	7 (1)

disease and histological grade of the primary tumour. Bone metastases were significantly more likely to be associated with a lower grade primary tumour ($\chi^2 = 7.90$, $P = 0.019$). Patients presenting with bone metastases were significantly more likely to have ER-positive primary tumours compared to patients who presented with metastatic disease at other sites ($\chi^2 = 19.76$, $P < 0.0001$). Bone metastases were also more likely to be associated with lymph node-positive primary tumours ($\chi^2 = 6.13$, $P = 0.047$). Bone metastases were more frequently observed in patients with Tubular Mixed primary tumours compared with Ductal NST ($\chi^2 = 5.03$, $P = 0.025$). No significant association with bone metastases was observed for the other tumour types including lobular carcinomas. Presentation with bone metastases was not related to the patient's age or the size of the primary tumour.

The radiographic appearances of the bone metastases and the tumour characteristics are shown in Table 3. There was no relationship between whether the bone metastases were visible or occult on plain radiographs and the histological grade of the primary tumour ($\chi^2 = 0.10$, $P = 0.608$) or the ER status of the primary tumour ($\chi^2 = 0.98$, $P = 0.322$). There was also no relationship between the radiographic appearances of the bone metastases (i.e. lytic, sclerotic or mixed) and the grade of the primary tumour ($\chi^2 = 2.52$, $P = 0.641$) or the ER status of the primary tumour ($\chi^2 = 0.58$, $P = 0.749$). There was no relationship between the radiographic appearance of the bone metastases and the type of primary tumour ($\chi^2 = 11.81$, $P = 0.461$).

Seven of the factors analysed were found to contribute significantly towards prolonged survival in patients presenting with bone metastases. These were ER status ($P = 0.0003$, Figure 1), histological grade ($P = 0.034$), additional sites of metastatic disease ($P = 0.0004$, Figure 2), patient age ($P = 0.0003$), number of hot spots on bone scan ($P = 0.040$) and metastasis-free interval ($P = 0.0045$, Figure 3). Levels of the tumour markers CA 15.3 and CEA at presentation were also significantly related to survival ($P = 0.0026$ and 0.017 , respectively, Figures 4 and 5). The radiographic appearance of the bone metastases, histological tumour type, lymph node stage, primary tumour size and ESR at presentation with bone metastases were not significantly related to survival.

Three of the factors analysed were also found to contribute significantly to survival in the 91 patients with bone as their only site of metastatic disease. These were ER status ($P = 0.018$), Ca 15.3 ($P = 0.025$) and metastasis-free interval ($P = 0.004$). In the same group of patients there was a trend for worsening survival if the CEA level was elevated at presentation, but this did not reach statistical significance.

A Cox multivariate analysis found that a long metastasis-free interval, absence of metastases at sites other than bone, ER-positive tumours, normal CEA and CA15.3 levels at presentation all contributed independently towards prolonged survival from time of presentation with bone metastases (Table 4).

Table 2 Correlation between presentation with bone metastases and primary tumour characteristics

Tumour characteristics	Bone metastases at presentation with metastatic disease		Univariate analysis
	Yes	No	
Histological grade (%)	1	14 (70)	$\chi^2 = 7.90$ $P = 0.0193$
	2	71 (68)	
	3	94 (52)	
ER status (%)	+VE	157 (69)	$\chi^2 = 19.755$ $P < 0.0001$
	-VE	60 (45)	
Lymph node stage (%)	1	29 (48)	$\chi^2 = 6.13$ $P = 0.0467$
	2	70 (68)	
	3	40 (60)	
Primary tumour size (mm) (%)	< 15	23 (55)	$\chi^2 = 4.389$ $P = 0.1114$
	15–30	56 (37)	
	> 30	35 (40)	
Patient age (%)	≤ 40	15 (56)	$\chi^2 = 2.889$ $P = 0.5766$
	41–50	46 (64)	
	51–60	56 (56)	
	61–70	59 (60)	
	> 70	91 (65)	
Tumour type (%)	Ductal NST	114 (56)	Ductal NST vs tubular mixed $\chi^2 = 5.03$ $P = 0.025$
	Tubular mixed	24 (77)	
	Lobular	25 (69)	Ductal NST vs lobular $\chi^2 = 2.22$ $P = 0.136$
	Mixed ductal and lobular	10 (50)	
	Pure tubular	2 (67)	

Table 3 Association between the radiographic appearance of the bone metastases and the primary tumour characteristics

Radiographic appearance of bone metastases	Histological grade (%)			ER status (%)		Tumour type (%)				
	1	2	3	+VE	-VE	Ductal NST	Tubular mixed	Lobular	Mixed ductal and lobular	Pure tubular
Occult	3 (21.5)	11 (15.5)	20 (22)	32 (21)	16 (28)	22 (20)	3 (12.5)	7 (28)	0	0
Visible										
Lytic	7 (50)	27 (38.5)	38 (41)	59 (39)	18 (31)	48 (43)	9 (37.5)	10 (40)	3 (25)	2 (100)
Mixed	3 (21.5)	14 (20)	16 (17)	30 (20)	11 (19)	19 (17)	7 (29)	3 (12)	4 (33)	0
Sclerotic	1 (7)	18 (26)	18 (20)	31 (20)	13 (22)	22 (20)	5 (21)	5 (20)	5 (42)	0
Univariate analysis	NS			NS		NS				

NS = no significant relationship.

DISCUSSION

Prognostic factors for metastatic breast carcinoma have received less attention than prognostic factors for primary disease. This may in part be due to the inherent difficulty in separating whether a factor is a 'pure' prognostic factor, a predictive factor for response to therapy or both. For primary breast carcinoma there are historical series where patients received no systemic adjuvant therapy and later series where they did. Consequently, the potential value of factors as prognostic or predictive can be teased out more easily. For patients with metastatic disease, where virtually all patients receive treatment, such distinctions are more difficult.

Many groups have studied prognostic factors in patients presenting with metastatic breast carcinoma. Patients with bone metastases make up the largest single group of patients presenting with metastatic disease. As a consequence, prognostic factors related to this specific group of patients are worthy of more detailed study.

Additional sites of metastatic disease at presentation with bone metastases dramatically worsened survival, with those patients presenting with lung and liver metastases doing significantly worse

than those patients presenting with bone metastases alone. Others have also confirmed the importance of site of initial metastases in determining prognosis (Blanco *et al*, 1990; Robertson *et al*, 1992; Coleman *et al*, 1998; Solomayer *et al*, 2000).

Factors that indicate a less aggressive tumour phenotype were associated with the development of bone metastases. Low-grade and ER-positive tumours were more likely to be associated with the development of bone metastases. Others have also found similar relationships (Koenders *et al*, 1991; Coleman *et al*, 1998; Solomayer *et al*, 2000). The same factors were also found to influence survival in patients presenting with bone metastases. Those with low-grade and ER-positive tumours showed significantly prolonged survival compared with patients with high-grade or ER-negative tumours. A shorter metastasis-free interval also had a negative impact on survival in patients with bone metastases. This confirms previous work recognising the prognostic importance of the metastasis-free interval (Solomayer *et al*, 2000). A short metastasis-free interval also tends to suggest a more aggressive, rapidly growing tumour.

The multivariate analysis showed ER status rather than histological grade as an independent prognostic factor for survival in patients presenting with bone metastases. The close relationship




Figure 1 Survival for patients with bone metastases by ER status.




Figure 3 Survival for patients with bone metastases by metastasis-free interval.




Figure 2 Survival for patients with bone metastases only compared to those with bone and other sites of metastatic disease.




Figure 4 Survival for patients with bone metastases by Ca 15.3 level (cutoff 35).

between ER status and grade is well recognised with ER activity occurring more frequently in well-differentiated tumours (Williams *et al*, 1987). The reason ER status correlates better with survival is in large part due to the fact that ER status predicts for response to endocrine therapy. The ER is involved in the actual pathway inhibited by endocrine therapy, whereas histological grade is a composite measure of three factors (tubule formation, nuclear pleomorphism and frequency of mitoses) which are themselves not based on a single cellular process. It is perhaps not surprising that ER status is better than histological grade at predicting survival.

One rather curious association was that patients with bone metastases were more likely to have had lymph node metastases at the time of diagnosis of their primary tumour. This may just be a

chance finding, but may also be explained by the close relationship between ER status and histological grade. Bone metastases are more likely to occur in ER-positive tumours. There is a strong correlation between ER positivity and well-differentiated tumours (Williams *et al*, 1987). Well-differentiated tumours are unlikely to metastasise unless lymph node positive, unlike poorly differentiated lymph node negative tumours which will still often metastasise. This may be a possible explanation for the association between lymph node metastases and bone metastases.

It is well established that for primary breast cancer lymph node stage, histological grade and to a lesser extent tumour size are powerful prognostic features. As has also been previously




Figure 5 Survival for patients with bone metastases by CEA level (cutoff 10).

Table 4 Cox multivariate analysis

Factor analysed	P-value	Coefficient
Presentation Ca 15.3	0.0105	0.0003
Metastasis-free interval	0.0411	0.127
ER status	0.0399	0.732
Presentation CEA	0.0055	0.0004
Presence of metastases at sites other than bone	0.0314	0.780

demonstrated (Williams *et al*, 1986; Robertson *et al*, 1992), once a patient develops metastatic disease then neither the lymph node status nor the size of the primary tumour is relevant as predictors of survival.

It is well known that the metastatic patterns of lobular and ductal carcinomas are different, with gastrointestinal and peritoneal metastases being more common in lobular carcinomas (Dixon *et al*, 1991). There has been debate in the literature as to whether tumour type has any bearing on the development of bone metastases. Tubular mixed primary tumours were more likely to develop bone metastases compared to Ductal NST tumours. This finding helps to support the argument that less-aggressive tumour phenotypes are more likely to be associated with the development of bone metastases. In common with several previous studies, we found no evidence that patients with lobular carcinoma were more likely to develop bone metastases compared to patients with ductal carcinomas (Dixon *et al*, 1991; Fondrinier *et al*, 1997). Others have suggested that lobular carcinomas have a tendency to metastasise to bone (Borst *et al*, 1993; Sastre-Garau *et al*, 1996).

Patient age does not appear to be a factor in the development of bone metastases, with bone metastases distributed fairly evenly across the age ranges. Others have also confirmed the lack of an age-related trend in the development of bone metastases (De La Monte *et al*, 1988). It has previously been observed that older women are more likely to have metastatic disease that remains confined to bone (Coleman *et al*, 1998). Along with others we have also found that survival for women with bone metastases was significantly worse over the age of 70 years (Coleman *et al*, 1998). It is difficult to know whether this reflects differences in treatment, or the increased likelihood of dying from other conditions. We

have seen a similar trend for worsening survival in our elderly patients with liver metastases, which seems in part explained by differences in treatment, with only 6.4% receiving chemotherapy compared to 56% of patients under 70 years (Wylde *et al*, 2002). Death from comorbid conditions has been put forward as an argument for the apparent poor survival in individuals over 70 years of age (Yanick *et al*, 2001). There may even be a link in some patients. For example, older patients have a higher incidence of osteoporosis, which in the presence of bone metastases may result in an increased incidence or earlier fracture rate. Fractures of long bones are known to carry significant mortality in the elderly.

The radiographic appearance of the bone metastases was not related to grade, ER status or type of primary tumour, nor did it have any bearing on patient survival. The only radiographic feature that did impact on patient survival was the number of hot spots on bone scan. Patients with a solitary hot spot on bone scan had significantly improved survival compared to patients with two or more hot spots. It has previously been reported that patients who have bone recurrence at initially only one or two sites on bone scan experience a survival advantage over those with more extensive skeletal metastases (Jacobson *et al*, 2001). Care needs to be taken when interpreting this finding, as a possible explanation for the apparent better outcome may be that a solitary hot spot on a bone scan has been incorrectly classified as malignant. Another explanation may relate to the reason for doing the bone scan, for instance, a patient with an asymptomatic tumour marker rise; in such a case, the apparent improved survival may simply be 'lead-time' bias.

The usefulness of blood tumour markers in the diagnosis and monitoring of response to treatment in patients with metastatic disease is well established (Breast Speciality Group of BASO, 1999; Robertson *et al*, 1999; Cheung *et al*, 2000, 2001). Much less has been written about the prognostic value of tumour markers. Correlations between raised preoperative levels of CA15.3 and CEA with poorer outcome have been reported (Molina *et al*, 1998; Shering *et al*, 1998; Ebeling *et al*, 1999; McLaughlin *et al*, 2000; Canizares *et al*, 2001). To our knowledge, the prognostic significance of an elevated CA15.3 and CEA in patients presenting with bone metastases has not been previously described. Several authors have commented on the correlation between overall tumour burden and CA15.3 levels (O'Hanlon *et al*, 1995; Tampellini *et al*, 2001). It is likely that elevated tumour markers reflect tumour burden in patients presenting with bone metastases.

Analysis of the subgroup with bone as their only site of metastatic disease revealed that patients with ER-negative tumour, elevated CA 15.3 level at presentation and a short metastasis-free interval experienced significantly reduced survival. This may have important implications for treatment, as patients with bone-only disease are traditionally treated with endocrine therapies alone. Patients with bone-only metastatic disease with ER-negative tumours, elevated CA15.3 levels at presentation and a short metastasis-free interval may benefit from more aggressive treatments, possibly with chemotherapy being considered as a first-line agent.

Prognostic factors are important for patient counselling and advising treatment options. This study has revealed several potential independent prognostic factors in patients presenting with bone metastases. These are ER status, metastasis-free interval, additional sites of metastases other than bone and elevated tumour marker levels. The factors that suggest a more aggressive tumour phenotype, such as negative ER status and short metastasis-free interval, are associated with a poorer outcome. Factors that are associated with a greater tumour burden also predict for reduced survival, these are raised tumour markers and the presence of extraosseous disease. Factors that suggest hormone sensitivity (a positive ER status) predict for longer survival. Awareness of the prognostic implications of these factors may aid the selection of the most appropriate treatment options in patients presenting with bone metastases.

REFERENCES

- Blanco G, Holli K, Heikkinen M, Kallioniemi O-P, Taskinen P (1990) Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. *Br J Cancer* **62**: 142–146
- Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. *Surgery* **114**: 637–642
- Breast Speciality Group of the British Association of Surgical Oncology (1999) The guidelines for the management of metastatic bone diseases in the United Kingdom. *Eur J Surg Oncol* **25**: 3–23
- Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, Penafiel R, Martinez P (2001) Preoperative values of CA15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. *Tumour Biol* **22**: 273–281
- Cheung KL, Evans AJ, Robertson JFR (2001) The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. *Breast Cancer Res Treat* **67**: 273–278
- Cheung KL, Graves CRL, Robertson JFR (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. *Cancer Treat Rev* **26**: 91–102
- Coleman RE, Rubens RD (1987) The clinical course of bone metastases. *Br J Cancer* **55**: 61–66
- Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. *Br J Cancer* **77**: 336–340
- De la Monte S, Hutchins GM, Moore GW (1988) Influence of age on the metastatic behaviour of breast carcinoma. *Hum Pathol* **5**: 529–534
- Dixon AR, Ellis IO, Elston CW, Blamey RW (1991) A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. *Br J Cancer* **63**: 634–635
- Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D (1999) Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer – univariate and multivariate analysis. *Anticancer Res* **19**: 2545–2550
- Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. *Histopathology* **20**: 479–489
- Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: experience from a large study with long term follow up. *Histopathology* **19**: 403–410
- Fondrinier E, Guerin O, Lorimier G (1997) A comparison of metastatic patterns of invasive ductal and lobular carcinomas of the breast: results of a matched study. *Bull Cancer* **84**: 1101–1107
- Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. *Cancer* **91**: 17–24
- Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad TJ (1991) Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. *Breast Cancer Res Treat* **18**: 27–32
- McLaughlin R, McGrath J, Grimes H, Given HF (2000) The prognostic value of the tumour marker CA 15-3 at initial diagnosis of patients with breast cancer. *Int J Biol Markers* **15**: 340–342
- Molina R, Jo J, Fillella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM (1998) C-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. *Breast Cancer Res Treat* **51**: 109–119
- O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF (1995) An evaluation of of preoperative CA 15.3 measurement in primary breast carcinoma. *Br J Cancer* **71**: 1288–1291
- Robertson JFR, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW (1992) Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. *Breast Cancer Res Treat* **22**: 221–227
- Robertson JFR, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JRC, Gronberg H, Kumpulainen E, Blamey RW (1999) The objective measurement of remission and progression in metastatic breast cancer. *Eur J Cancer* **35**: 47–53
- Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand J-C, Fourquet A, Pouillart P (1996) Infiltrating lobular carcinoma of the breast. *Cancer* **77**: 113–120
- Shering SG, Sherry F, Mc Dermott EW, O Higgins NJ, Duffy MJ (1998) Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. *Cancer* **83**: 2521–2527
- Solomayer E-F, Diel IJ, Meyberg GC, Gollan C, Baster G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. *Breast Cancer Res Treat* **59**: 271–278
- Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M, Dogliotti L (2001) Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. *Tumour Biol* **22**: 367–373
- Williams MR, Todd JH, Ellis IO, Dowle CS, Haybittle JL, Elston CW, Nicholson RI, Griffiths K, Blamey RW (1987) Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. *Br J Cancer* **55**: 67–73
- Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW, Griffiths K (1986) Survival patterns in hormone treated advanced breast cancer. *Br J Surg* **73**: 752–755
- Wylid L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JFR, Evans AJ (2002) Prognostic factors for patients with hepatic metastases from breast cancer. In preparation
- Yanick R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and co-morbidity in post menopausal breast cancer patients aged 55 years and older. *J Am Med Assoc* **285**: 885–892